| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematopoietic Stem Cell Transplantation | 33 | 2026 | 1280 | 2.540 |
Why?
|
| Graft vs Host Disease | 15 | 2024 | 694 | 1.210 |
Why?
|
| Hodgkin Disease | 8 | 2022 | 307 | 1.090 |
Why?
|
| T-Lymphocytes | 16 | 2024 | 1722 | 1.040 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 7 | 2016 | 174 | 0.840 |
Why?
|
| Salvage Therapy | 3 | 2021 | 174 | 0.820 |
Why?
|
| Lymphoma | 4 | 2021 | 327 | 0.730 |
Why?
|
| Antigens, Neoplasm | 5 | 2021 | 393 | 0.680 |
Why?
|
| Transplantation, Autologous | 13 | 2022 | 254 | 0.640 |
Why?
|
| Cell- and Tissue-Based Therapy | 2 | 2021 | 151 | 0.640 |
Why?
|
| Transplantation, Homologous | 20 | 2024 | 670 | 0.580 |
Why?
|
| Herpesvirus 4, Human | 11 | 2018 | 638 | 0.530 |
Why?
|
| Bone Marrow Transplantation | 5 | 2014 | 589 | 0.510 |
Why?
|
| Immunosuppressive Agents | 4 | 2014 | 663 | 0.510 |
Why?
|
| Transplantation Conditioning | 9 | 2022 | 328 | 0.490 |
Why?
|
| T-Lymphocytes, Cytotoxic | 8 | 2013 | 511 | 0.480 |
Why?
|
| Alemtuzumab | 7 | 2024 | 89 | 0.420 |
Why?
|
| Skin Ulcer | 1 | 2014 | 32 | 0.410 |
Why?
|
| Thalidomide | 1 | 2014 | 36 | 0.410 |
Why?
|
| Immunotherapy, Adoptive | 7 | 2018 | 960 | 0.400 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 5 | 2013 | 895 | 0.400 |
Why?
|
| Middle Aged | 43 | 2026 | 28601 | 0.380 |
Why?
|
| Lymphoma, T-Cell | 2 | 2018 | 60 | 0.380 |
Why?
|
| Multiple Myeloma | 3 | 2021 | 177 | 0.370 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 5 | 2013 | 91 | 0.360 |
Why?
|
| Herpesvirus 6, Human | 3 | 2017 | 53 | 0.350 |
Why?
|
| Adult | 41 | 2026 | 31282 | 0.340 |
Why?
|
| Antibodies, Monoclonal | 6 | 2008 | 981 | 0.340 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 3 | 2016 | 151 | 0.320 |
Why?
|
| Roseolovirus Infections | 2 | 2007 | 29 | 0.320 |
Why?
|
| Stem Cell Transplantation | 4 | 2006 | 227 | 0.320 |
Why?
|
| Antigens, CD19 | 6 | 2018 | 192 | 0.300 |
Why?
|
| Antilymphocyte Serum | 3 | 2006 | 44 | 0.290 |
Why?
|
| Aged | 26 | 2026 | 21025 | 0.290 |
Why?
|
| Interleukin-2 | 4 | 2014 | 236 | 0.290 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2022 | 1272 | 0.280 |
Why?
|
| Burkitt Lymphoma | 2 | 2006 | 131 | 0.280 |
Why?
|
| Gout | 1 | 2011 | 169 | 0.280 |
Why?
|
| Male | 52 | 2026 | 64957 | 0.280 |
Why?
|
| CD40 Ligand | 4 | 2011 | 65 | 0.270 |
Why?
|
| Leukemia | 3 | 2022 | 387 | 0.270 |
Why?
|
| Lymphoma, Follicular | 1 | 2007 | 29 | 0.260 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 3 | 2013 | 27 | 0.250 |
Why?
|
| Paramyxoviridae Infections | 1 | 2007 | 49 | 0.250 |
Why?
|
| Humans | 69 | 2026 | 131163 | 0.250 |
Why?
|
| Metapneumovirus | 1 | 2007 | 54 | 0.250 |
Why?
|
| Lymphoma, Non-Hodgkin | 3 | 2018 | 163 | 0.250 |
Why?
|
| Paresis | 1 | 2006 | 32 | 0.250 |
Why?
|
| Cancer Vaccines | 4 | 2011 | 191 | 0.250 |
Why?
|
| Hemoglobin SC Disease | 1 | 2006 | 7 | 0.240 |
Why?
|
| Rituximab | 3 | 2022 | 170 | 0.240 |
Why?
|
| Viral Matrix Proteins | 5 | 2018 | 108 | 0.240 |
Why?
|
| Cytomegalovirus Infections | 2 | 2024 | 223 | 0.230 |
Why?
|
| Leukemia, Myeloid | 1 | 2006 | 80 | 0.230 |
Why?
|
| Receptors, Antigen, T-Cell | 3 | 2020 | 502 | 0.230 |
Why?
|
| Female | 47 | 2026 | 70963 | 0.230 |
Why?
|
| Cytokines | 1 | 2011 | 1339 | 0.230 |
Why?
|
| Antibodies, Neoplasm | 5 | 2008 | 55 | 0.220 |
Why?
|
| Hematologic Neoplasms | 5 | 2021 | 315 | 0.220 |
Why?
|
| Young Adult | 11 | 2022 | 10103 | 0.220 |
Why?
|
| Antiviral Agents | 2 | 2024 | 807 | 0.210 |
Why?
|
| Lymphoma, B-Cell | 3 | 2018 | 147 | 0.210 |
Why?
|
| Quinazolines | 1 | 2024 | 176 | 0.200 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2022 | 1336 | 0.190 |
Why?
|
| Genetic Therapy | 3 | 2018 | 713 | 0.190 |
Why?
|
| Tissue Donors | 6 | 2021 | 506 | 0.190 |
Why?
|
| Autoimmune Diseases | 2 | 2018 | 262 | 0.190 |
Why?
|
| Recurrence | 10 | 2022 | 1489 | 0.190 |
Why?
|
| Treatment Outcome | 19 | 2018 | 12936 | 0.180 |
Why?
|
| Lymphocyte Transfusion | 2 | 2021 | 55 | 0.180 |
Why?
|
| Adolescent | 17 | 2022 | 20987 | 0.180 |
Why?
|
| Carmustine | 1 | 2022 | 22 | 0.180 |
Why?
|
| Neomycin | 2 | 2000 | 36 | 0.180 |
Why?
|
| Melphalan | 1 | 2022 | 45 | 0.180 |
Why?
|
| Graft vs Leukemia Effect | 2 | 2021 | 39 | 0.180 |
Why?
|
| Bone Marrow | 2 | 2021 | 317 | 0.180 |
Why?
|
| Cytarabine | 1 | 2022 | 100 | 0.170 |
Why?
|
| Seizures | 1 | 2006 | 890 | 0.170 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2021 | 125 | 0.160 |
Why?
|
| Leukemia, Myeloid, Acute | 3 | 2021 | 614 | 0.150 |
Why?
|
| Bone Marrow Cells | 1 | 2021 | 243 | 0.150 |
Why?
|
| Health Services Accessibility | 1 | 2026 | 712 | 0.150 |
Why?
|
| Tumor Escape | 2 | 2018 | 65 | 0.140 |
Why?
|
| Photosensitivity Disorders | 1 | 2018 | 10 | 0.140 |
Why?
|
| Lymphocyte Depletion | 3 | 2024 | 124 | 0.140 |
Why?
|
| Voriconazole | 1 | 2018 | 29 | 0.140 |
Why?
|
| Antigens, CD | 4 | 2011 | 410 | 0.140 |
Why?
|
| Acute Disease | 4 | 2011 | 1153 | 0.130 |
Why?
|
| Granulomatous Disease, Chronic | 1 | 2018 | 68 | 0.130 |
Why?
|
| Antipyrine | 2 | 1988 | 4 | 0.130 |
Why?
|
| DNA Virus Infections | 1 | 2017 | 22 | 0.130 |
Why?
|
| Diltiazem | 2 | 1988 | 13 | 0.130 |
Why?
|
| DNA Viruses | 1 | 2017 | 31 | 0.130 |
Why?
|
| Epstein-Barr Virus Infections | 2 | 2018 | 289 | 0.130 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 2 | 2006 | 35 | 0.120 |
Why?
|
| Genetic Markers | 1 | 1998 | 587 | 0.120 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 2016 | 29 | 0.120 |
Why?
|
| Child | 16 | 2022 | 26341 | 0.120 |
Why?
|
| Retrospective Studies | 10 | 2024 | 17753 | 0.120 |
Why?
|
| Prognosis | 4 | 2021 | 4886 | 0.110 |
Why?
|
| Vidarabine | 3 | 2010 | 91 | 0.100 |
Why?
|
| Diagnostic Imaging | 1 | 2016 | 305 | 0.100 |
Why?
|
| Leukapheresis | 1 | 2013 | 14 | 0.100 |
Why?
|
| Viruses | 1 | 2014 | 117 | 0.100 |
Why?
|
| Blood Donors | 1 | 2013 | 58 | 0.100 |
Why?
|
| Time Factors | 7 | 2018 | 6196 | 0.100 |
Why?
|
| Combined Modality Therapy | 4 | 2021 | 1216 | 0.090 |
Why?
|
| Lung Diseases | 2 | 2009 | 398 | 0.090 |
Why?
|
| Remission Induction | 5 | 2016 | 306 | 0.090 |
Why?
|
| Gene Transfer Techniques | 2 | 2011 | 344 | 0.090 |
Why?
|
| Azoles | 1 | 2012 | 9 | 0.090 |
Why?
|
| Budesonide | 1 | 2012 | 18 | 0.090 |
Why?
|
| Cushing Syndrome | 1 | 2012 | 22 | 0.090 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2014 | 236 | 0.090 |
Why?
|
| Colchicine | 1 | 2011 | 40 | 0.090 |
Why?
|
| Immunophenotyping | 4 | 2016 | 332 | 0.090 |
Why?
|
| Quality of Life | 1 | 2021 | 2082 | 0.090 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2013 | 60 | 0.090 |
Why?
|
| Virus Diseases | 1 | 2014 | 285 | 0.090 |
Why?
|
| Cytomegalovirus | 3 | 2024 | 259 | 0.080 |
Why?
|
| Retroviridae | 3 | 2016 | 182 | 0.080 |
Why?
|
| CD28 Antigens | 1 | 2011 | 76 | 0.080 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2013 | 544 | 0.080 |
Why?
|
| Allopurinol | 1 | 2011 | 79 | 0.080 |
Why?
|
| B-Lymphocytes | 1 | 2013 | 509 | 0.080 |
Why?
|
| Steroids | 1 | 2011 | 170 | 0.080 |
Why?
|
| Primary Myelofibrosis | 1 | 2011 | 51 | 0.080 |
Why?
|
| Follow-Up Studies | 5 | 2018 | 5196 | 0.080 |
Why?
|
| Transplantation Chimera | 2 | 2008 | 44 | 0.080 |
Why?
|
| Lymphocyte Subsets | 1 | 2009 | 40 | 0.080 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2012 | 301 | 0.070 |
Why?
|
| Cell Proliferation | 5 | 2018 | 2465 | 0.070 |
Why?
|
| Neoplasm Staging | 2 | 2016 | 1287 | 0.070 |
Why?
|
| DNA, Viral | 2 | 2007 | 448 | 0.070 |
Why?
|
| Histocompatibility | 2 | 2006 | 42 | 0.070 |
Why?
|
| Adenoviridae | 4 | 2013 | 579 | 0.070 |
Why?
|
| Theophylline | 1 | 1988 | 23 | 0.070 |
Why?
|
| Verapamil | 1 | 1988 | 43 | 0.070 |
Why?
|
| Virus Integration | 1 | 2007 | 37 | 0.060 |
Why?
|
| Lymphocyte Activation | 3 | 2018 | 633 | 0.060 |
Why?
|
| Antigens, CD34 | 1 | 2007 | 97 | 0.060 |
Why?
|
| Positron Emission Tomography Computed Tomography | 2 | 2018 | 75 | 0.060 |
Why?
|
| Encephalitis, Viral | 1 | 2007 | 20 | 0.060 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2008 | 161 | 0.060 |
Why?
|
| Antigen-Presenting Cells | 1 | 2007 | 124 | 0.060 |
Why?
|
| Minoxidil | 1 | 1986 | 4 | 0.060 |
Why?
|
| Body Mass Index | 1 | 2013 | 1717 | 0.060 |
Why?
|
| Survival Analysis | 4 | 2016 | 1483 | 0.060 |
Why?
|
| Exchange Transfusion, Whole Blood | 1 | 2006 | 11 | 0.060 |
Why?
|
| Filgrastim | 1 | 2006 | 13 | 0.060 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2006 | 500 | 0.060 |
Why?
|
| Benzazepines | 1 | 1986 | 43 | 0.060 |
Why?
|
| Anemia, Aplastic | 1 | 2006 | 60 | 0.060 |
Why?
|
| Feasibility Studies | 3 | 2016 | 824 | 0.060 |
Why?
|
| Anti-Bacterial Agents | 1 | 1998 | 2596 | 0.060 |
Why?
|
| Major Histocompatibility Complex | 1 | 2006 | 48 | 0.060 |
Why?
|
| Immune System Diseases | 1 | 2006 | 58 | 0.060 |
Why?
|
| Leukemia, B-Cell | 1 | 2005 | 25 | 0.060 |
Why?
|
| Lymphocyte Count | 3 | 2014 | 118 | 0.060 |
Why?
|
| Antibodies, Monoclonal, Humanized | 5 | 2008 | 570 | 0.060 |
Why?
|
| Cell Culture Techniques | 1 | 2006 | 274 | 0.060 |
Why?
|
| Disease-Free Survival | 3 | 2013 | 905 | 0.060 |
Why?
|
| Leukocyte Common Antigens | 1 | 2005 | 84 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2026 | 3829 | 0.050 |
Why?
|
| Antineoplastic Agents | 3 | 2013 | 1826 | 0.050 |
Why?
|
| Graft Rejection | 1 | 2008 | 552 | 0.050 |
Why?
|
| Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 1 | 2004 | 15 | 0.050 |
Why?
|
| Acetates | 1 | 2024 | 77 | 0.050 |
Why?
|
| Myelin Basic Protein | 1 | 2004 | 67 | 0.050 |
Why?
|
| Drug Interactions | 3 | 2012 | 237 | 0.050 |
Why?
|
| Autoantigens | 1 | 2004 | 97 | 0.050 |
Why?
|
| Cell Line | 3 | 2013 | 2552 | 0.050 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2006 | 463 | 0.050 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2010 | 821 | 0.050 |
Why?
|
| Phosphoproteins | 1 | 2006 | 448 | 0.050 |
Why?
|
| Recovery of Function | 1 | 2005 | 449 | 0.050 |
Why?
|
| Herpesviridae Infections | 1 | 2004 | 148 | 0.050 |
Why?
|
| Glycoproteins | 1 | 2005 | 346 | 0.050 |
Why?
|
| Recombinant Proteins | 1 | 2006 | 1319 | 0.050 |
Why?
|
| Child, Preschool | 7 | 2018 | 15110 | 0.050 |
Why?
|
| Genetic Vectors | 2 | 2013 | 892 | 0.050 |
Why?
|
| Positron-Emission Tomography | 2 | 2016 | 279 | 0.050 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 2002 | 27 | 0.040 |
Why?
|
| Lymphocytes | 1 | 2023 | 344 | 0.040 |
Why?
|
| Graft Survival | 3 | 2011 | 465 | 0.040 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2021 | 55 | 0.040 |
Why?
|
| Antibodies, Viral | 1 | 2007 | 1176 | 0.040 |
Why?
|
| Healthcare Disparities | 1 | 2026 | 523 | 0.040 |
Why?
|
| Demography | 1 | 2021 | 237 | 0.040 |
Why?
|
| Allografts | 1 | 2021 | 220 | 0.040 |
Why?
|
| Multiple Sclerosis | 1 | 2004 | 395 | 0.040 |
Why?
|
| CD5 Antigens | 2 | 2010 | 33 | 0.040 |
Why?
|
| Nuclear Proteins | 1 | 2006 | 1211 | 0.040 |
Why?
|
| Liver | 1 | 1986 | 1796 | 0.040 |
Why?
|
| Anti-HIV Agents | 1 | 2002 | 345 | 0.030 |
Why?
|
| Chimerism | 1 | 2018 | 29 | 0.030 |
Why?
|
| Philadelphia Chromosome | 1 | 1998 | 41 | 0.030 |
Why?
|
| Genes, Viral | 1 | 1998 | 155 | 0.030 |
Why?
|
| Pancytopenia | 1 | 2018 | 40 | 0.030 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2018 | 33 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 1998 | 239 | 0.030 |
Why?
|
| Unrelated Donors | 1 | 2018 | 72 | 0.030 |
Why?
|
| Sarcoidosis | 1 | 1998 | 50 | 0.030 |
Why?
|
| Drug Resistance, Microbial | 1 | 1998 | 195 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2013 | 1071 | 0.030 |
Why?
|
| Red-Cell Aplasia, Pure | 1 | 1997 | 2 | 0.030 |
Why?
|
| Cells, Cultured | 2 | 2018 | 2885 | 0.030 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 1998 | 103 | 0.030 |
Why?
|
| Mitosporic Fungi | 1 | 1997 | 5 | 0.030 |
Why?
|
| Erythropoiesis | 1 | 1997 | 39 | 0.030 |
Why?
|
| Adenoviruses, Human | 1 | 2017 | 96 | 0.030 |
Why?
|
| Administration, Oral | 2 | 2012 | 711 | 0.030 |
Why?
|
| BK Virus | 1 | 2017 | 58 | 0.030 |
Why?
|
| Skin Diseases | 1 | 1998 | 143 | 0.030 |
Why?
|
| Interferon-alpha | 1 | 1998 | 238 | 0.030 |
Why?
|
| Whole-Body Irradiation | 2 | 2006 | 60 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2016 | 2065 | 0.030 |
Why?
|
| Mycoses | 1 | 1997 | 110 | 0.030 |
Why?
|
| Antifungal Agents | 1 | 2018 | 292 | 0.030 |
Why?
|
| Workflow | 1 | 2016 | 144 | 0.030 |
Why?
|
| Prospective Studies | 3 | 2014 | 6459 | 0.030 |
Why?
|
| Adoptive Transfer | 1 | 2016 | 235 | 0.030 |
Why?
|
| Kinetics | 2 | 1986 | 1088 | 0.030 |
Why?
|
| Phenotype | 2 | 2018 | 4497 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 787 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2016 | 294 | 0.030 |
Why?
|
| Monitoring, Physiologic | 1 | 2016 | 376 | 0.030 |
Why?
|
| Species Specificity | 1 | 2014 | 470 | 0.020 |
Why?
|
| Protein Engineering | 1 | 2013 | 61 | 0.020 |
Why?
|
| Hepatitis C | 1 | 1997 | 381 | 0.020 |
Why?
|
| Blood Cell Count | 1 | 2013 | 65 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2007 | 1205 | 0.020 |
Why?
|
| Etoposide | 1 | 2013 | 112 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2018 | 713 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2013 | 276 | 0.020 |
Why?
|
| Cell Separation | 1 | 2013 | 218 | 0.020 |
Why?
|
| South America | 1 | 2012 | 45 | 0.020 |
Why?
|
| Immunotherapy | 2 | 2011 | 768 | 0.020 |
Why?
|
| North America | 1 | 2012 | 255 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2014 | 765 | 0.020 |
Why?
|
| Iatrogenic Disease | 1 | 2012 | 121 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 2013 | 428 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 2011 | 91 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2011 | 308 | 0.020 |
Why?
|
| Infant | 3 | 2014 | 13352 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 1618 | 0.020 |
Why?
|
| Plasmids | 1 | 2011 | 449 | 0.020 |
Why?
|
| Incidence | 1 | 2018 | 3360 | 0.020 |
Why?
|
| Hyaluronan Receptors | 1 | 2010 | 64 | 0.020 |
Why?
|
| Risk Factors | 3 | 2013 | 11074 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2011 | 716 | 0.020 |
Why?
|
| Stem Cells | 1 | 2014 | 702 | 0.020 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2009 | 152 | 0.020 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2009 | 101 | 0.020 |
Why?
|
| Gene Expression | 1 | 2013 | 1481 | 0.020 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2010 | 160 | 0.020 |
Why?
|
| Immunity | 1 | 2009 | 178 | 0.020 |
Why?
|
| Medical Records | 1 | 2009 | 174 | 0.020 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2010 | 194 | 0.020 |
Why?
|
| Immunization | 1 | 2010 | 269 | 0.020 |
Why?
|
| Cytochrome P-450 Enzyme Inhibitors | 1 | 1988 | 4 | 0.020 |
Why?
|
| Gastrointestinal Diseases | 1 | 2012 | 343 | 0.020 |
Why?
|
| Living Donors | 1 | 2008 | 111 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 1988 | 126 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2012 | 1490 | 0.020 |
Why?
|
| Half-Life | 1 | 1988 | 149 | 0.020 |
Why?
|
| Severe Combined Immunodeficiency | 1 | 2008 | 107 | 0.020 |
Why?
|
| Radiography | 1 | 2009 | 743 | 0.020 |
Why?
|
| Cerebrospinal Fluid Proteins | 1 | 2007 | 24 | 0.020 |
Why?
|
| Metabolic Diseases | 1 | 2008 | 143 | 0.020 |
Why?
|
| Chemistry | 1 | 1986 | 24 | 0.020 |
Why?
|
| Chemical Phenomena | 1 | 1986 | 46 | 0.020 |
Why?
|
| Electrochemistry | 1 | 1986 | 25 | 0.020 |
Why?
|
| Drug Stability | 1 | 1986 | 56 | 0.020 |
Why?
|
| Respiratory Tract Infections | 1 | 2009 | 298 | 0.020 |
Why?
|
| Tacrolimus | 1 | 2006 | 100 | 0.010 |
Why?
|
| Cyclosporine | 1 | 2006 | 132 | 0.010 |
Why?
|
| B7-2 Antigen | 1 | 2005 | 16 | 0.010 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2005 | 37 | 0.010 |
Why?
|
| Pneumonia | 1 | 2009 | 341 | 0.010 |
Why?
|
| Biopsy | 1 | 2009 | 1239 | 0.010 |
Why?
|
| Siblings | 1 | 2006 | 201 | 0.010 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2006 | 193 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1986 | 318 | 0.010 |
Why?
|
| CD52 Antigen | 1 | 2005 | 6 | 0.010 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2005 | 71 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 2010 | 680 | 0.010 |
Why?
|
| United States | 1 | 2021 | 12072 | 0.010 |
Why?
|
| CD3 Complex | 1 | 2005 | 96 | 0.010 |
Why?
|
| Virus Activation | 1 | 2005 | 88 | 0.010 |
Why?
|
| Coculture Techniques | 1 | 2005 | 230 | 0.010 |
Why?
|
| Histocompatibility Testing | 1 | 2005 | 108 | 0.010 |
Why?
|
| Texas | 1 | 2013 | 3686 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2005 | 304 | 0.010 |
Why?
|
| Immune System | 1 | 2005 | 100 | 0.010 |
Why?
|
| Methotrexate | 1 | 2006 | 350 | 0.010 |
Why?
|
| Age Factors | 1 | 2011 | 2825 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2008 | 1445 | 0.010 |
Why?
|
| Age Distribution | 1 | 2005 | 422 | 0.010 |
Why?
|
| Genes, Immunoglobulin | 1 | 2004 | 33 | 0.010 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2004 | 52 | 0.010 |
Why?
|
| Antigens, Viral | 1 | 2005 | 395 | 0.010 |
Why?
|
| Thymus Gland | 1 | 2004 | 104 | 0.010 |
Why?
|
| Platelet Transfusion | 1 | 2004 | 55 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2007 | 1447 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2011 | 1928 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2009 | 2304 | 0.010 |
Why?
|
| Survival Rate | 1 | 2008 | 2114 | 0.010 |
Why?
|
| Radiography, Thoracic | 1 | 2004 | 144 | 0.010 |
Why?
|
| Forkhead Transcription Factors | 1 | 2005 | 371 | 0.010 |
Why?
|
| Viral Load | 1 | 2004 | 416 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 2004 | 192 | 0.010 |
Why?
|
| Cell Division | 1 | 2004 | 718 | 0.010 |
Why?
|
| Antibodies | 1 | 2004 | 322 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2004 | 544 | 0.010 |
Why?
|
| Horses | 1 | 2001 | 94 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2004 | 639 | 0.010 |
Why?
|
| Cell Movement | 1 | 2004 | 876 | 0.010 |
Why?
|
| Drug Resistance | 1 | 2001 | 242 | 0.010 |
Why?
|
| Rabbits | 1 | 2001 | 575 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2011 | 6797 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2001 | 732 | 0.010 |
Why?
|
| Data Collection | 1 | 2001 | 370 | 0.010 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2001 | 333 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2009 | 1545 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2005 | 3748 | 0.010 |
Why?
|
| Erythroid Precursor Cells | 1 | 1997 | 19 | 0.010 |
Why?
|
| Aspergillus fumigatus | 1 | 1997 | 41 | 0.010 |
Why?
|
| Global Health | 1 | 2001 | 626 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2001 | 1295 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2006 | 3147 | 0.010 |
Why?
|
| HIV Infections | 1 | 2002 | 2049 | 0.000 |
Why?
|
| Animals | 1 | 2001 | 33912 | 0.000 |
Why?
|